Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.52 |
| ▸ | PREP | P48147 | 3/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1022998 | 0.99 | DPP4 (0.51) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL1023086 | 0.84 | DPP4 (0.45) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL1023379 | 0.83 | DPP4 (0.44) | DPP4DPP8DPP7PREPDPP9 | |
| Hydrochloric Acid SCHEMBL1072916 | 0.82 | DPP4 (0.43) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL1070015 | 0.81 | PREP (0.50) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL1346883 | 0.74 | DPP4 (0.59) | DPP4DPP8DPP7PREPDPP9 | |
| Hydrochloric Acid SCHEMBL1348449 | 0.73 | DPP4 (0.58) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL4890308 | 0.68 | DPP4 (1.00) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL1019926 | 0.68 | DPP4 (0.40) | DPP4DPP8DPP7PREPDPP9 | |
| SCHEMBL5222258 | 0.68 | DPP4 (0.73) | DPP4DPP8DPP7PREPDPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118305-A1 | COMPOUNDS | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | disclosed |
| EP-1517907-B1 | AZABICYCLO-OCTANE AND NONANE DERIVATIVES WITH DDP-IV INHIBITING ACTIVITY | SANOFI AVENTIS (FR) | 2011-01-12 | — | — | EP | disclosed |
| US-7781455-B2 | Compounds | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20050153973-A1 | (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; enzyme inhibitors; diabetes | SANOFI-AVENTIS (FR) | 2005-07-14 | — | — | US | disclosed |
| EP-1517907-A2 | AZABICYCLO-OCTANE AND NONANE DERIVATIVES WITH DDP-IV INHIBITING ACTIVITY | Sanofi-Aventis (FR) | 2005-03-30 | — | — | EP | disclosed |
| WO-2003106456-A2 | NEW COMPOUNDS | SANOFI-SYNTHELABO (FR) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153973-A1 | (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; enzyme inhibitors; diabetes | DPP4, DPP8, DPP3 | DPP4 1/4885DPP8 2/4885DPP7 4/4885 |
| US-20110118305-A1 | COMPOUNDS | DPP4, DPP3, DPP8 | DPP4 1/4885DPP8 3/4885DPP7 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.